Tvardi Therapeutics
TVRD
183 hedge funds and large institutions have $387M invested in Tvardi Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 71 reducing their positions, and 23 closing their positions.
223% more call options, than puts
Call options by funds: $4.35M | Put options by funds: $1.35M
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
5% more capital invested
Capital invested by funds: $368M → $387M (+$19.3M)
1% more funds holding
Funds holding: 181 → 183 (+2)
0.07% more ownership
Funds ownership: 1.57% → 1.65% (+0.07%)
32% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.7M |
| 2 |
PA
Pinnacle Associates
New York
|
+$4.08M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$3.42M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.06M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.57M |
| 3 |
Renaissance Technologies
New York
|
-$2.3M |
| 4 |
C
Chescapmanager
Baltimore,
Maryland
|
-$1.48M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.21M |
TVRD Hedge Fund Activity: Q1 2022 in Review
183 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2022, worth a combined $387M — up 5.3% from $368M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TVRD positions and 23 closed out — a net gain of 3 holders — while 48 added to existing stakes and 71 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $5.7M. The largest seller was Soleus Capital Management, cutting an estimated $3.06M.
- 183 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2022, up from 181 in Q4 2021.
- Funds reported $387M of Tvardi Therapeutics stock for Q1 2022, up 5.3% quarter-over-quarter.
- 26 funds opened new Tvardi Therapeutics positions in Q1 2022 and 23 closed out, a net change of +3 holders.
- The largest Tvardi Therapeutics buyer in Q1 2022 was Farallon Capital Management, an estimated $5.7M added.
- The largest Tvardi Therapeutics seller in Q1 2022 was Soleus Capital Management, an estimated $3.06M sold.
Based on aggregated 13F filings for Q1 2022.